Scholar Rock(US:SRRK) Yahoo Finance·2026-02-22 17:57Core Insights - Redmile Group increased its stake in Scholar Rock Holding Corporation by purchasing 1,316,390 shares, valued at approximately $49.37 million based on quarterly average pricing [1][2] - The quarter-end value of Redmile's position in Scholar Rock increased by $84.58 million, reflecting both the acquisition of additional shares and market price movements [2] Company Overview - Scholar Rock Holding Corporation is a clinical-stage biotechnology company focused on developing therapies that modulate protein growth factor signaling, addressing unmet medical needs in neuromuscular, oncological, and fibrotic indications [6] - The company has a proprietary platform and is positioned to capitalize on innovative science in high-impact therapeutic areas through strategic collaborations and a focused pipeline [6] Financial Metrics - As of February 17, 2026, Scholar Rock's stock price was $46.45, with a market capitalization of $4.78 billion [4] - The company reported a net income of -$353.43 million (TTM) and a one-year price change of 25.71% [4] Investment Implications - The purchase by Redmile Group indicates a strong commitment to Scholar Rock, which now represents approximately 17% of the fund's assets under management [7][10] - Scholar Rock is expected to submit a Biologics License Application for apitegromab in spinal muscular atrophy, with a potential U.S. launch anticipated following approval this year [9] - The company had approximately $365 million in cash as of December 31, providing a runway into 2027 and reducing near-term dilution risk for investors [9] Market Performance - Scholar Rock's shares have increased by about 26% over the past year, outperforming the broader market and indicating that investors are recognizing the value of regulatory progress and pipeline depth [11] - The company is also developing additional programs, including FSHD and the SRK-439 myostatin inhibitor, which expand its potential market opportunities [11]